4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor

Journal of Medicinal Chemistry
Shailesh N MistryPeter J Scammells

Abstract

Positive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (M1 mAChR) are a promising strategy for the treatment of the cognitive deficits associated with diseases including Alzheimer's and schizophrenia. Herein, we report the design, synthesis, and characterization of a novel family of M1 mAChR PAMs. The most active compounds of the 4-phenylpyridin-2-one series exhibited comparable binding affinity to the reference compound, 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA) (1), but markedly improved positive cooperativity with acetylcholine, and retained exquisite selectivity for the M1 mAChR. Furthermore, our pharmacological characterization revealed ligands with a diverse range of activities, including modulators that displayed both high intrinsic efficacy and PAM activity, those that showed no detectable agonism but robust PAM activity and ligands that displayed robust allosteric agonism but little modulatory activity. Thus, the 4-phenylpyridin-2-one scaffold offers an attractive starting point for further lead optimization.

References

Feb 1, 2017·ACS Chemical Neuroscience·Aaron M BenderCraig W Lindsley
Apr 15, 2017·Bioorganic & Medicinal Chemistry Letters·Shawn Johnstone, Jeffrey S Albert
Jul 20, 2019·Journal of Receptor and Signal Transduction Research·Sara BdiouiTerry Kenakin
Feb 23, 2020·Biomolecules·Jan Jakubik, Esam E El-Fakahany
Apr 18, 2018·The Journal of Pharmacy and Pharmacology·Stuti VermaAwanish Kumar
Mar 28, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sean P MoranP Jeffrey Conn

Citations

Jan 9, 1999·Acta Crystallographica. Section B, Structural Science·H W Yang, B M Craven
Dec 17, 2002·Nature Neuroscience·Stephan G AnagnostarasAlcino J Silva
Oct 3, 2006·Annual Review of Pharmacology and Toxicology·Lauren T MayArthur Christopoulos
Jul 17, 2007·Trends in Pharmacological Sciences·Katie LeachArthur Christopoulos
Dec 18, 2007·Pharmacology & Therapeutics·C J LangmeadCharlie Reavill
May 6, 2008·British Journal of Pharmacology·C J LangmeadJ Watson
Jul 3, 2008·The American Journal of Psychiatry·Anantha ShekharChristian C Felder
Oct 10, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·C K JonesP J Conn
Oct 30, 2008·Journal of Neurochemistry·Elizabeth Scarr, Brian Dean
Feb 10, 2009·Trends in Pharmacological Sciences·P J ConnC W Lindsley
Sep 1, 2009·Proceedings of the National Academy of Sciences of the United States of America·Lei MaWilliam J Ray
Dec 17, 2009·Bioorganic & Medicinal Chemistry Letters·Feng V YangC W Lindsley
Dec 17, 2009·Psychopharmacology·Morgane ThomsenS Barak Caine
Sep 3, 2010·Current Neuropharmacology·Fadi Massoud, Serge Gauthier
Mar 19, 2011·Journal of Medicinal Chemistry·Nicholas A Meanwell
May 12, 2011·The Journal of Pharmacology and Experimental Therapeutics·Marla L WattChristian C Felder
Jun 28, 2011·The American Journal of Pathology·Rodrigo MedeirosFrank M LaFerla
Nov 17, 2011·The Journal of Biological Chemistry·Meritxell CanalsArthur Christopoulos
Jun 23, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Gregory J DigbyP J Conn
Oct 1, 2013·Journal of Medicinal Chemistry·Tracey HuynhBen Capuano
Jan 21, 2014·The Journal of Biological Chemistry·Alaa Abdul-RidhaArthur Christopoulos
Mar 8, 2014·Journal of Medicinal Chemistry·Ana Z GonzalezJulio C Medina
Jun 26, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A GhoshalP J Conn

Related Concepts

Peptidylglycine Monooxygenase Activity
Cricetulus
Familial Alzheimer Disease (FAD)
Derivatives
Schizophrenia
Structure-Activity Relationship
Pyridones
Quinolines
3-(4-bromobenzoyl)-2-quinolinecarboxaldehyde
Chinese Hamster Ovary Cell

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here